ロード中...
Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
OBJECTIVES: Iron is an essential element for cell proliferation and growth processes. We have reported that deferasirox (DFX), an oral iron chelator, showed antiproliferative activity against pancreatic cancer cells. This study aimed to elucidate the effects of combination of gemcitabine (GEM), stan...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6033369/ https://ncbi.nlm.nih.gov/pubmed/29983871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25421 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|